You are here: start ยป treatment_adrenaline

Adrenaline (Treatment)

Adrenaline (Treatment)

1. Overview

Adrenaline is an endogenous catecholamine, and is used pharmacologically as a sympathomimetic agent. It acts on the ฮฒ and ฮฑ adrenoreceptors with dose-dependent selectivity. It is used to treat anaphylaxis, symptomatic bradycardia (e.g. in ฮฒ-blocker toxicity), and cardiac arrest.

2. Toxicologic Indications & Dosing

2.1 Anaphylaxis

  • Also see: anaphylaxis.
  • Adult:
    • ๐Ÿ’Š Adrenaline 0.5 mg IM (0.5 mL of 1:1,000), q5min PRN.
  • Child:
    • ๐Ÿ’Š๐Ÿ‘ถ Adrenaline 10 micrograms/kg IM (0.01 mL/kg of 1:1,000), q5min PRN. Min dose 0.1 mL, max dose 0.5 mL.
  • IV adrenaline may be given only by experienced specialists in an appropriate setting, as the dose requirements are different.

2.2 Bradycardia

  • Adult:
    • ๐Ÿ’Š Adrenaline 5-20 microgram IV, q3min PRN.
    • ๐Ÿ’Š Adrenaline 2-10 microgram/min IV infusion, titrate to response.
  • Child:
    • ๐Ÿ’Š๐Ÿ‘ถ Adrenaline 10 microgram/kg IV (0.1 mL/kg of 1:10,000), q3min PRN.
    • ๐Ÿ’Š๐Ÿ‘ถ Adrenaline 0.1-1.5 microgram/kg/min IV infusion, titrate to response.

2.3 Cardiac Arrest

  • Also see: cardiac arrest.
  • Adult: ๐Ÿ’Š Adrenaline 1 mg IV, every 2 cycles.
  • Child: ๐Ÿ’Š๐Ÿ‘ถ Adrenaline 10 microgram/kg IV, every 2 cycles.

3. Cautions & Contraindications

There are no absolute contraindications to the use of adrenaline in a life-threatening situation.

  • Overtreatment may result in hypertension and tachyarrhythmias.
  • โ†‘ serum lactate.
  • Myocardial ischemia.

4. Special Populations

Pregnancy rating: A (AU/NZ)

Lactation: Excreted in breast milk, but potential effects on breastfed infant is unknown.

5. Adverse Effects

  • CVS: hypertension, tachyarrhythmias, myocardial ischemia.
  • CNS: anxiety, tremor.
  • Skin: tissue necrosis if extravasates.
  • Metabolic: hyperglycemia, hyperlactatemia.

6. Pharmacology

6.1 Pharmacodynamics

Mechanism of action: Dose-dependent adrenoceptor activity, with ฮฒ-agonist effects predominate at low doses, and added ฮฑ-agonist effects at higher doses.

6.2 Pharmacokinetics

Absorption:

  • Oral bioavailability: 0%.

Distribution:

  • Vd: 0.1-0.2 L/kg.
  • Lipid solubility:
    • Does not cross BBB
    • Crosses placenta
    • Excreted in breast milk
  • Protein binding: 50%

Metabolism: Rapidly metabolized by COMT and MAO into metanephrine and 3,4-dihydroxymandelic acid, then ultimately into vanillylmandelic acid.

Excretion:

  • Elimination tยฝ: 2-3 mins.
  • Renal clearance: Renally excreted, mostly as inactive metabolites.

6.3 Pharmaceutics

Formulation:

  • Ampoules containing 1000 microgram/1 mL or 1000 microgram/10 mL.
  • Autoinjector with varying doses (commonly 0.15 mg, 0.3 mg, 0.5 mg). Various brands exist, e.g. EpiPen, Emerade, Auvi-Q.

7. References

Useful general references:

treatment_adrenaline.txt ยท Last modified: 2025/04/16 04:20